Illumina: shedding light on genetics

Illumina, the genome sequencing specialist, is a leader in a thriving market. Long-term investors should buy now, says Mike Tubbs.


Illumina is well entrenched in the clinical diagnostic market

The science of who we are and how we got here has advanced in leaps and bounds in recent years. Take genome sequencing, the process of identifying the order of genetic letters' in an organism's DNA, or genetic code; reading' the genetic structure, essentially.

The whole human genome consists of three billion of these letters. It cost about $3bn and took 13 years for the very first decoding of a human genome to be completed in 2003.But today high-tech machines supplied by Illumina (Nasdaq: ILMN) do the same job for less than $1,000 in mere days.

An exciting field

For instance, plant and animal genomics speeds up the improvement of crops and farm animals originally carried out by selective breeding. Genome sequencing has identified many genetic markers in farm animals that are associated with desirable traits such as resistance to a particular disease. This facilitates breeding animals with this particular trait but without reductions in other desirable qualities.

Meanwhile, early detection of cancer can increase the chances of survival by a factor of ten. Since some tumour cell DNA (which is subtly different from normal cell DNA) circulates in the blood, sequencing of DNA collected from the blood can identify the presence of tumour cells.

Illumina, then, provides essential diagnostic and research tools for the growing life science and biotechnology sector. It is the clear global leader in genome sequencing, with around 75% of the overall market, a figure that continues to grow. More than 90% of sequenced genetic material is likely to have passed through an Illumina machine and there are 13,000 Illumina systems in active use globally.

Fund platform and research group Morningstar estimates that the genome sequencing market can grow to over $20bn, compared with Illumina's 2018 salesof $3.33bn.An important source of recurring revenue comes from the high-margin disposable products or equipment (such as reagents for testing that require replacing) that customers need to use with their sequencing systems. Usage increases both with the installed base and with increased machine use. Other services include training, servicing and consulting.

Protected from competition

Then there are regulatory hurdles for potential competitors, with Illumina's MiSeq platform the only genome sequencing instrument approved by America's Food and Drug Administration (FDA). The FDA is likely to want to add further regulations for sequencing in the clinical diagnostic market, entrenching Illumina's advantage.

For example, Illumina is likely to fund clinical trials to prove its instruments' worth for cancer screening tests. If these result in FDA approval, this will provide further barriers to entry for competitors. Cancer screening is a high-growth area since selection of the best treatment from the many new generation immuno-oncology drugs requires genetic profiles of tumours and patients.

Share price dip is a buying opportunity

Illumina (Nasdaq: ILMN)
Investment measureInvestment ratio
Share price$282.86p/e for 202037.7
Market cap$41.6bnNet cash$1.52bn
Next results (Q1) dueLate April 2019Yieldn/a
Recent results20172018Change
Operating profit$687m$928m+35.1%
Earnings per share$4.00$5.72+43.0%

Illumina's technological lead is maintained both by its exceptionally high investment in R&D (18.7% of sales compared with Samsung's 7.2% or Google-parent Alphabet's 14.5%) and by bolt-on acquisitions.

In the past year Illumina has acquired Pacific Biosciences, a sequencing company, for $1.2bn and Edico Genome, a start-up data analysis company, for $100m. It has also partnered with Loxo Oncology on cancer diagnostics for solid tumours. Pacific Biosiences gives Illumina access to a specialised set of sequencing applications expected to grow to a value of $2.5bn a year by 2022.

Illumina has a strong balance sheet, a record of profitability and a history of shrewd capital allocation. Its forward price/earnings (p/e) ratio for 2019 is 39.5, high but a reflection of the impressive growth opportunities in the years ahead.

Growth expectations are based on the way genomic sequencing is creating new research applications and moving into many existing clinical diagnostic markets.

The shares, up 76% in the past five years, dipped after the 2018 results because of cautious guidance of 13%-14% revenue increase in 2019. They are down 19% from last September's peak a buying opportunity.


University spin-outs: where to find companies involved in cutting-edge science
Share tips

University spin-outs: where to find companies involved in cutting-edge science

Universities are innovation incubators and often launch businesses involved in fast-growing fields ranging from biotechnology to artificial intelligen…
24 Sep 2021
Investing in football clubs: how you can profit from the beautiful game
Share tips

Investing in football clubs: how you can profit from the beautiful game

Football clubs may often be money pits for oligarchs, but they are also huge global brands, says John Chambers – and investors are now starting to rec…
24 Sep 2021
Share tips of the week – 24 September
Share tips

Share tips of the week – 24 September

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
24 Sep 2021
Carbon emissions trading: how to profit from the price of pollution

Carbon emissions trading: how to profit from the price of pollution

Carbon-emission allowances are still an esoteric market, but one that looks set to grow. This new fund could help you cash in.
21 Sep 2021

Most Popular

Two shipping funds to buy for steady income
Investment trusts

Two shipping funds to buy for steady income

Returns from owning ships are volatile, but these two investment trusts are trying to make the sector less risky.
7 Sep 2021
Should investors be worried about stagflation?
US Economy

Should investors be worried about stagflation?

The latest US employment data has raised the ugly spectre of “stagflation” – weak growth and high inflation. John Stepek looks at what’s going on and …
6 Sep 2021
A nightmare 1970s scenario for investors is edging closer
Investment strategy

A nightmare 1970s scenario for investors is edging closer

Inflation need not be a worry unless it is driven by labour market shortages. Unfortunately, writes macroeconomist Philip Pilkington, that’s exactly w…
17 Sep 2021